Analysis Topic: Companies Analysis
The analysis published under this topic are as follows.Saturday, April 26, 2014
I’d Like You to Meet “Cortana” My Artificial Intelligence / Companies / Technology
Michael A. Robinson writes: I’d like to introduce you to Cortana.
And let me tell you: She’s awesome.
Cortana can search the Internet, set up reminders, shift calendar appointments, manage your mishmash of meetings, find restaurants, send text messages, and place phone calls. And, as good as she is right now, Cortana only seems to get better the more that I deal with her. The longer we work together, the more she seems to understand my habits and anticipate my needs.
Read full article... Read full article...
Friday, April 25, 2014
Electronic Cigarettes Shake Up the Tobaco Industry / Companies / Sector Analysis
In the last few years, we have seen relatively few examples of true market innovation. Progress in cell phone, computer, and automobile technology has stalled and this makes it difficult to identify companies that are poised for real growth over the next 5-10 years. But it looks as though an exception can be made here in the electronic cigarette industry, which has made some major advances in recent years when compared to the traditional cigarette products that have seemingly been around forever. These innovations will have a major impact not only on the health of cigarette smokers but on the broader trajectory in many areas of the marketplace, as well. Here, we will look at some of the ways electronic cigarettes will alter the landscape -- both from a health perspective and from a market perspective.
Read full article... Read full article...
Friday, April 25, 2014
Biotech Long-Term Profit Machines Stock Prices on Sale / Companies / BioTech
Michael A. Robinson writes: Market volatility has suddenly created some great opportunities, including those in the biotech sector.
Supporting the inevitable ascent of the industry is the release of a steady stream of compounds that have helped them rack up billions in new revenue.
Consider that since it began trading in early 2001, the iShares Nasdaq Biotechnology Index (Nasdaq: IBB) is up 130%. That's more than triple the S&P 500's 13-year return of 43%.
Read full article... Read full article...
Wednesday, April 23, 2014
Why Mohamed El-Erian Left Pimco / Companies / Corporate News
In his first interview since leaving PIMCO, Dr. Mohammed Aly El-Erian told Bloomberg's Betty Liu this morning that he is very surprised by the media attention he received around his departure and the reason he left was "to interact with others," to "step back", "to do something different," spend more time with his daughter and travel less.
Read full article... Read full article...
Tuesday, April 22, 2014
The Corporate Earnings Beat That's Perfect for This Market / Companies / Investing 2014
Last Wednesday, the Milpitas, Calif.-based SanDisk Corporation (Nasdaq: SNDK) reported first-quarter results that smashed analyst expectations, and the company's shares shot up 6% in after-hours trading.
But our Chief Investment Strategist Keith Fitz-Gerald saw that beat coming and put readers out in front of it.
He talked to me about its recent stellar performance...
Read full article... Read full article...
Monday, April 21, 2014
Fast Rising Pump Prices Counterattack / Companies / Gas - Petrol
Peter Krauth writes: Since the early 1970s, most major oil deals have been transacted in "petrodollars."
But that system has become increasingly challenged in recent years.
The conflict in Ukraine right now has only served to exacerbate things.
Read full article... Read full article...
Friday, April 18, 2014
Build Biotech Wealth on Solid Platforms / Companies / BioTech
Potential. That's what every investor is looking for in a biotech investment. Grant Zeng of Zacks Small-Cap Research zeroes in on three primary factors when he looks at whether a particular company has the potential to succeed in the fast-moving life sciences industry. In this interview with The Life Sciences Report, Zeng dissects his process and names 10 companies that have survived his exacting examination.
The Life Sciences Report: As an analyst you focus on promising junior biotechs. What primary qualities do you look for in a company that you rate hold or outperform? And what do you think makes a junior biotech attractive to someone who might want to acquire it?
Read full article... Read full article...
Thursday, April 17, 2014
Obamacare Proof Stocks / Companies / Healthcare Sector
Now that all the key deadlines for Obamacare have finally taken effect, a lot of tech investors are busy trying to figure out how this will affect their portfolios.
It's easy to see why. This is the largest and most fundamental change to hit the healthcare sector in decades.
Read full article... Read full article...
Thursday, April 17, 2014
Hidden Australian Life Sciences Bio-tech Growth Stocks / Companies / BioTech
To find undiscovered stories, investors must venture into unfamiliar territory. In this interview with The Life Sciences Report, we go halfway around the world to speak with Scott Power of Morgans Financial Ltd. about companies under coverage in Australia. Power helps investors get comfortable with the idea of putting money into newfound names, and unveils four strong ideas that could invigorate adventuresome portfolios and investors hungering for excitement.
The Life Sciences Report: You are based in Brisbane, Australia, where your firm, Morgans Financial, is headquartered. All the names on your coverage list have traded on the Australian Securities Exchange (ASX). How would you compare investing in Australian biotech or medtech stocks to investing in those same types of stocks in the U.S. or Europe?
Read full article... Read full article...
Thursday, April 17, 2014
When Corporate Earnings Disappoint In A Market Priced For Perfection / Companies / Corporate Earnings
After today’s market close there was a flurry of earnings announcements, some of which were way low. Not bad, mind you. In fact they were pretty good. But because Wall Street analysts were expecting more in order to justify current stock prices, the disappointments led to big price declines in the aftermarket:
Read full article... Read full article...
Thursday, April 17, 2014
Disrupting Big Data Status Quo / Companies / Tech Stocks
Big data is taking over the world, and Rory Armes and Ken Scott of Gener8 Media Corp. know why. In this interview with Streetwise Reports' Special Situations, the two Vancouver-based upstarts discuss the tribulations of getting in on the ground floor of the newest developments in information technology—and the many potential rewards.
Read full article... Read full article...
Wednesday, April 16, 2014
There Is No Biotech Stock Bubble; Here's the Real Story / Companies / BioTech
Ernie Tremblay writes: Some analysts feel that the biotech sector's recent tumble is evidence of the biotech bubble bursting.
But they're wrong; the market is simply in a period of adjustment.
The premise behind the bubble idea is that biotech companies as a group are overvalued, that their market caps aren't supported by performance. In other words, that their perceived value is all smoke and mirrors.
Read full article... Read full article...
Wednesday, April 16, 2014
These CEOs Will Make Investors Rich / Companies / Investing 2014
William Patalon writes: During the 30 years I've spent as a business journalist and financial columnist, I've developed a long list of personal axioms that have helped me identify "Best of Breed" investments.
These axioms touch on such topic areas as finance, marketing, intellectual property, and even competitive threats. But some of the most important of my personal investment aphorisms have to do with leadership and a company's management team.
Read full article... Read full article...
Friday, April 11, 2014
Six Ways to Profit from Russia’s Geopolitical Posturing / Companies / Investing 2014
George Leong writes: The situation in Crimea should be closely monitored as it pertains to Europe and the eurozone. Russia is a major trading partner with the eurozone as well, supplying about 40% of the energy requirements in the area. That is why an escalation in Crimea could devastate the region, especially at a time when the economy is finally growing in the eurozone.
Read full article... Read full article...
Friday, April 11, 2014
Bill Gross to El-Erian: 'Come on, Mohamed, Tell Us Why' You Resigned PIMCO / Companies / Corporate News
Pimco's Bill Gross spoke with Bloomberg Television's Trish Regan today and opened up about Mohamed El-Erian's departure and reflects on his personal role at the company.
Gross explained he was "extremely disappointed" in El-Erian reluctance to speak up and explain why he resigned: "He hasn't spoken up, and that's a mystery to us and quite frankly an extreme disappointment....He simply said that he wasn't the man to take the company forward. And he constantly repeated that without explaining it."
Read full article... Read full article...
Friday, April 11, 2014
Don't Miss the Boat on Big Biotech Catalysts: Keith Markey / Companies / BioTech
Keith Markey, veteran analyst and science director of Griffin Securities, tells us the 2014 pipeline calendar is positively glowing with important milestones that could ignite portfolios. In this interview with The Life Sciences Report, Markey talks about four powerful biotech names with exciting early- to late-stage development projects and one medical device and supply company with serious growth potential. Be warned—huge catalysts are on the horizon that investors won't want to miss.
Read full article... Read full article...
Wednesday, April 09, 2014
Profits in This Market Are About to Rocket / Companies / Investing 2014
Peter Krauth writes: It's not often a new kid makes it onto the commodities block.
So I'm going to step beyond the realm of regular resources to discuss one that's burgeoning.
But like most new things that push existing boundaries, it's controversial.
Read full article... Read full article...
Monday, April 07, 2014
Biotech Investing - Finding the Blockbuster That Will Make You Rich / Companies / BioTech
Ernie Tremblay writes: In the pharmaceutical industry, a "blockbuster" is any drug that brings in $1 billion or more in revenue per year.
It's the prize that every biotech hopes to win - and every biotech investor hopes to cash in on.
So how do you spot one in the making? If the market suspects a drug candidate has blockbuster potential, catalysts (events like positive clinical study results and regulatory milestones) will give its manufacturer's share price a big, big boost.
Read full article... Read full article...
Thursday, April 03, 2014
What the Google (Nasdaq: GOOG) Stock Split Means for Investors / Companies / Google
Kyle Anderson writes: The Google Inc. (Nasdaq: GOOG) stock split happens tomorrow (Wednesday, April 2), meaning Google shareholders of record as of March 27 will own two shares tomorrow for every share they own today.
Following the split, Google will have twice as many shares outstanding than it currently does. Google's "Class A" shares will trade under the ticker GOOGL, while the company's "Class C" shares will remain on the company's current ticker GOOG.
Read full article... Read full article...
Wednesday, April 02, 2014
The Best Stock Investing Play in a Trillion-Dollar Market / Companies / Investing 2014
Michael A. Robinson writes: In the go-go 1980s - back when the hit movie Wall Street told us that "Greed Is Good" -Carl Icahn was known as a "corporate raider"... and was revered for his windfall-producing decisiveness.
Icahn is still around. And he's still active. Only now - in the politically correct 2000s - he's known as an "activist investor" who's gone up against the likes of Apple Inc. (Nasdaq: AAPL) and eBay Inc. (Nasdaq: EBAY).
Read full article... Read full article...